About DeepVax

Enhancing Global Access to Disease-Modifying Therapies

By shifting from monoclonal antibody therapy to active vaccination, we reduce the cost of these disease-modifying therapies by at least an order of magnitude. This cost reduction allows us to reach a far greater number of patients, including those in financially constrained settings.

Prof. Martin Bachmann pioneered this technology in companion animals, establishing the foundations at Saiba Animal Health AG, which was recently acquired by Boehringer Ingelheim (BI), a leader in animal health.